Fig. 3

ANXA1 promotes ICC cell proliferation and growth in vitro and vivo. A-B: Validation of ANXA1 knockdown in HUCCT1 cell lines and overexpression in RBE cell line by western blot and RT-PCR. C: EDU assay to detect the proliferative capacity of ANXA1 knockdown or overexpression. D: Plate cloning assay to detect the proliferative capacity of ANXA1 knockdown HUCCT1 and HCCC9810 cells and RBE overexpression. E: CCK-8 assay to detect the proliferative capacity of ANXA1 knockdown HUCCT1 and HCCC9810 cells and RBE overexpression. F: Xenograft mouse model of tumors from HUCCT1 cells with ANXA1 knockdown and RBE cells with ANXA1 overexpression. G: Volume and weight changes of xenograft tumors from HUCCT1 cells with ANXA1 knockdown. H: Volume and weight changes of xenograft tumors from RBE cells with ANXA1 overexpression. I: Immunohistochemical staining of KI67 and PCNA in mouse subcutaneous xenograft tumor tissues. Data are representative of three (A, B, C, D, E) or five (G, H) independent experiments. Unpaired two-tailed Student’s t-tests (B, C(right), D(right), H(right)); One-way ANOVA with Dunnett’s test (A, C(left), D(left), G(right)); two-way ANOVA (E, G(left), H(left)); Log-rank (Mantel–Cox) test (H, I). **, p < 0.01; ***, p < 0.001; ns, not significant. Data are mean ± SD